KZIA | Kazia Therapeutics Limited Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.8850 - 3.15
52 Week Range	1.9000 - 15.80
Beta	1.91
Implied Volatility	736.49%
IV Rank	51.13%
Day's Volume	59,669
Average Volume	121,385
Shares Outstanding	33,285,078
Market Cap	10,052,091
Sector	Healthcare
Industry	Biotechnology
IPO Date	1999-01-06

Valuation
Profitability
Growth
Health
P/E Ratio	-0.47
Forward P/E Ratio	N/A
EPS	-6.44
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	9
Country	Australia
Website	KZIA

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

KZIA's peers: CTMX, ASMB, OCUL, SPRO, ACHL, SLS, NLSP, MREO, ARAV, DAWN, ZIVO, RNXT, KTTA, QNRX, ABIO, BNOEF, OKYO, CADL, ANEB, CINGW, NRIX, SEER, QSI, HCWB, MNOV

*Chart delayed

Analyzing fundamentals for KZIA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see KZIA Fundamentals page.

Watching at KZIA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on KZIA Technicals page.